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A B S T R A C T
Thus far, no human MERS-CoV infections have been reported from Israel. Evidence for the circulation of MERS-
CoV in dromedaries has been reported from almost all the countries of the Middle East, except Israel. Therefore,
we aimed to analyze MERS-CoV infection in Israeli camelids, sampled between 2012 and 2017. A total of 411
camels, 102 alpacas and 19 llamas' sera were tested for the presence of antibodies to MERS-CoV. Our ﬁndings
indicate a lower MERS-CoV seropositivity among Israeli dromedaries than in the surrounding countries, and for
the ﬁrst time naturally infected llamas were identiﬁed. In addition, nasal swabs of 661 camels, alpacas and
lamas, obtained from January 2015 to December 2017, were tested for the presence of MERS-CoV RNA. All nasal
swabs were negative, indicating no evidence for MERS-CoV active circulation in these camelids during that time
period.
1. Introduction
Middle East respiratory syndrome coronavirus (MERS-CoV), a
lineage 2C-betacoronavirus, was ﬁrst identiﬁed in 2012 [1]. Serologic
surveys identiﬁed>90% MERS-CoV–speciﬁc antibody seroprevalence
in adult dromedary camels (Camelus dromedarius) in many countries in
the Middle East and Africa. Moreover MERS-CoV viral RNA was de-
tected in the nasal swabs of dromedaries in Qatar, Oman, Saudi Arabia,
Egypt and United Arab Emirates (UAE) [2].
Conﬁrmed MERS human cases in Iran, Jordan, Kuwait, Lebanon,
Oman, Saudi Arabia, Qatar, UAE and Yemen, were epidemiologically
linked to camels, indicating camels as a potential source of human in-
fections [3]. Alpacas (Vicugna pacos) and llamas (Lama glama) are also
susceptible to experimental MERS-CoV infections [4–6] but only al-
pacas were found to be naturally infected until now.
Presently, the highest MERS-CoV prevalence in humans has been
documented in Saudi Arabia, as reported by the World Health
Organization, whereas no cases have been reported from Israel despite
the occurrence human-camel contact.
Approximately 155,000 Bedouins, traditionally a semi-nomadic
pastoralist population, inhabit the Negev Desert and breed camels,
sheep and goats. The estimated dromedary camel population in Israel is
3000–5000. In addition, the largest herd of alpacas and llamas, outside
South America, is in the Negev. Since the virus is circulating in the
surrounding countries, we aimed to assess the presence of MERS-CoV
speciﬁc antibodies and viral RNA among camelids in Israel.
2. Material and methods
2.1. Samples
A total of 411 blood samples from dromedary camels, 102 from
alpacas and 19 from llamas were collected during 2012–2017 (Table 1,
Fig. 1). The sampled camels were from 20 farms, 18 located in the
Negev, one in central Israel and one in the north (Fig. 1). The camels
included 37 were males and 374 were females, and their ages ranged
from 1month to 12 years. The alpacas and lamas sampled from one
farm located in the Negev. The alpacas include 65 females and 37 males
and their ages ranged from 6month to 15 years. The lamas include 8
females and 11 males and their ages ranged from 2 years to 20 years.
A total of 540 nasal swabs from camels, 102 from alpacas and 19
from llama were collected between January 2015 and November 2017.
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Camel samples were collected from 486 females and 54 males, aged
from 1month to 19 years. The alpacas and lamas were from one farm in
the Negev.
2.2. Virus neutralizing antibodies test (VNT)
The virus neutralizing antibodies test (VNT) is the gold standard
assay for the serological diagnosis of the MERS-CoV infection. The
camel, alpaca and llama sera were tested at a dilution of 1:20–1:2560
for the presence of neutralizing antibodies to MERS-CoV by the virus
neutralization test (VNT) [7]. Brieﬂy, sera were heat-inactivated by
incubating for 30min at 56 °C. Two-fold serial dilutions of sera were
prepared in 96-well plates, starting at a 1:10 dilution. Sera reacting
from a dilution of 1:20 and up were considered positive. Live MERS-
CoV was diluted in Iscove's Modiﬁed Dulbecco's Medium (IMDM),
supplemented with Penicillin, Streptomycin and 1% FBS, to a dilution
of 2000 TCID50/ml. Subsequently, 50 μl virus suspensions was added to
each well of plates and the plates were incubated at 37 °C for 1 h. Next,
virus-serum mixtures were incubated on 96 well plates containing Vero
cells for 1 h followed by washing with PBS and incubation with IMDM-
1% FBS for 5 days, after which the cytopathic eﬀect was scored.
2.3. ELISA
MERS-CoV antibodies were screened by ELISA (Euroimmun AG,
Lubeck, Germany), according to the ELISA manufacturer's instructions.
Brieﬂy, diluted serum samples (1100) were incubated in ELISA plate
wells, coated with MERS-CoV S1 antigen. Positive, negative and cali-
brator samples were included. Antibodies were detected by adding
peroxidase-labeled rabbit anti–camel IgG. Results were reported as the
optical density (OD) ratio, which was calculated as the OD value of the
sample divided by the calibrator OD value. We used cutoﬀ values re-
commended by the ELISA kit manufacturer: a ratio of< 0.8 was
considered negative, ≥0.8 to<1.1 was considered borderline, and
≥1.1 was considered positive [8]. Borderline reacting sera were not
included in the comparison.
2.4. RNA extraction and detection by real-time RT-PCR
The swab specimens were suspended in 2ml PBS, incubated for 1 h
at room temperature and then clariﬁed by centrifugation at 1000 rpm
for 10min. The supernatants were recovered for extraction and were
stored at −80 °C until analysis. Total nucleic acid was extracted from
200 μl swab samples using Invisorb Spin virus RNA mini kit (STRATEC,
molecular GmbH, Berlin, Germany), according to the manufacturer's
instructions. Extracted RNA was tested for the presence of MERS-CoV
RNA by real-time reverse transcription-quantitative polymerase chain
reaction (qrt RT-PCR) hydrolysis probe assay using Bio Rad CFX 96 Real
Time detection system (Bio Rad, Hercules, CA, USA). The primers and
probe encompassed upstream the envelope gene (UpE) [9].
2.5. Statistical method
Serological data were entered into an Excel worksheet and analyzed
using Excel functions. Results from Excel were veriﬁed using public
access statistical software (https://www.medcalc.org/calc/diagnostic_
test.php, http://vassarstats.net/kappa.html, http://vassarstats.net/
prop1.html
3. Results
MERS-CoV speciﬁc antibodies in Israeli camels were analyzed using
Table 1
Total sera collected between 2012 and 2017, by location and species.
No. Village Year of Collection Total
2012 2013 2014 2015 2016 2017
Camels
1 Mas'udin Al Azazme 4 5 – 11 16 15 51
2 Segev- Shalom 2 – – – – 2
3 En Habesor 12 10 – 31 20 – 73
4 Aroer 9 – – – – 9
5 Tarabin AS-Sani 4 6 39 19 68
6 Sede Boqer 7 2 – – 1 – 10
7 Abu Qureinat 4 – – 12 – 16
8 Abu Rubeia 9 – – 3 22 27 61
9 Qabboa – 3 – – 9 12
10 Rahat – – 2 2 18 10 32
11 Azem – 2 – 1 3 6
12 Revivim – – – 14 14 – 28
13 Hura – – – 1 1
14 Shibli – 2 – – – 2
15 Arara – 7 – – 7
16 Mitzpe Ramon 2 – 2
17 Ksifea 1 24 25
18 Tel Sheva 1 1
19 Nokdim 3 3
20 Azuz 2 2
Total camels 51 31 8 114 102 105 411
Alpaca
Mitzpe Ramon 102
Total 102 102
Llamas
Mitzpe Ramon 19
Total 19 19
Fig. 1. Locations of camelids sampled for MERS CoV monitoring.
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two serological assays, VNT and ELISA. Until the year 2014 sera were
analyzed only by VNT, as being a gold standard, performed by the re-
ference laboratory. With the expansion of screening activities in Israel,
in subsequent years, sera were analyzed by ELISA also, as enabled by
safety requirements, thus both assays were performed in parallel. Fig. 2
shows the neutralization titers and the percentage positives with con-
ﬁdence level (CI) detected by the two assays per year. While the VNT
was performed on all sera collected from 2012 to 2017, ELISA was
performed only on the sera collected between 2015 and 2017.
We initially tested 90 camel sera, obtained from 2012 to 2014, using
VNT. Most camels were adults, 3 years and more, thus analysis of in-
fection by age is not possible. MERS-CoV neutralizing antibodies for the
year 2012 showed a seropositivity of 72.5% point estimate proportion
(PEP) (CI: 60.3%, 84.8%) at a 95% conﬁdence level (CL). The ser-
opositivity seemed to drop to 38.7%, during 2013. Sera from 2015 to
2017 were analyzed by both ELISA and VNT (Fig. 2A, B). The ser-
oprevalence of MERS-CoV antibodies obtained using ELISA did not
signiﬁcantly diﬀer from those obtained using VNT, as both PEPs and Cls
overlapped (Fig. 2). Most camel sera were collected from the Southern
part of Israel, except of 2 farms (nos. 14 and 15) (Table 1, Fig. 1), from
the Northern and Central Israel, respectively. Only one camel serum
from farm no. 14 was positive.
The sensitivity and speciﬁcity of the two serological assays, VNT
and ELISA, between 2015 and 2017 were determined on 271 camels
sera that were tested in parallel by the two assays. Taking VNT as the
gold-standard the sensitivity of the ELISA when compared to the VNT
assay was 91.71% (CI: 86.70%, 95.29%) and the speciﬁcity was 93.33%
(Cl: 86.05%, 97.51%).
We performed a kappa evaluation of the agreement between the
ELISA and the VNT tests, receiving a value of 0.82 (CI: 0.75, 0.89; 95%
CL). As deﬁned by Cohen [10], 0.82 shows a perfect strength of
agreement.
Overall for 2012 to 2017, 254 camels (61.8%) were VNT positive,
with neutralizing titers from 20 to ≥2560 (Fig. 2A). In 184 camels
(70.4%), low antibody titers, between 20 and 320, were measured,
while 70 camels (29.6%) had high antibody titers, between 320 to
≥2560. No antibodies were detected (titer < 20) in 155 (37.8%) ca-
mels.
During 2016, blood was collected from 102 alpacas and 19 llamas
and tested by ELISA and by VNT (Fig. 3A). Using ELISA the alpaca and
llama sera showed a seroprevalence of 34.3 and 36.8%, respectively (35
and 7 positives). Using VNT, 30 alpacas and 6 llamas were positive, and
PEPs were 29.4% (CI: 21.4%, 38.8%) and 31.5% (CI: 15.3%, 54.0%)
respectively. The VNT titers were relatively low, ranging from 20 to 320
(Fig. 3B). The two camels sampled from the same farm as the alpacas
and lamas were negative for MERS-CoV by both VNT and ELISA.
The nasal swabs of 540 camels, 102 alpacas and 19 llamas, collected
between January 2015 and December 2017, were analyzed for the
presence of MERS-CoV RNA. All nasal swabs were negative for the
presence of MERS-CoV RNA, providing no evidence for active circula-
tion, at least until 2017, of MERS-CoV in the Negev camels.
4. Discussion
We present the ﬁrst serological and molecular survey for MERS–CoV
Fig. 2. Detection of MERS-CoV antibodies in sera of dromedary camels, Israel
2012–2017. A) Percentage of MERS-CoV antibody positive by VNT and ELISA.
Point estimate proportions (PEP) and conﬁdence intervals (CI) are given per
year. B) Serum neutralizing antibody titers by VNT. Red line indicated median;
dotted black lines at 20 indicates cutoﬀ for the VNT assay. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
Fig. 3. Detection of MERS-CoV antibodies in sera of alpacas and lamas by the VNT and ELISA. A) Percentage of MERS CoV antibody positive by VNT and ELISA per
year. B) Serum neutralizing antibody titers by VNT. Dotted black line at 20 indicates cutoﬀ for the VNT assay.
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infection among Israeli camelids, from 2012 to 2017. Camels showed an
average MERS–CoV seroprevalence of 60.6% between 2012 and 2017
by VNT an average seroprevalence of 62.9% by ELISA between 2015
and 2017, without any detection of viral RNA in the nasal swabs of the
540 camels. The presence of virus-speciﬁc neutralizing antibodies
suggests that Israeli camels were exposed to MERS-CoV in the past. The
VNT assay was more sensitive than the ELISA, which had only 91.7%
sensitivity when compared to VNT assay. That feature could be related
to the fact that the ELISA coating antigen was the MERS-CoV spike S1
protein, whereas the VNT assay employed complete virions that could
reveal antibodies against other viral proteins. Alternatively, whereas
the ELISA detects only IgG, the VNT detects any isotype of antibodies
which could be IgG, IgM or IgA. The VNT assay was also more speciﬁc
than the ELISA, which had a calculated speciﬁcity of only 93.33% when
compared to VNT. In addition, the higher strength of the VNT assay as
compared to ELISA might be attributed by the fact that borderline sera
by ELISA were not considered.
For the period from 2012 to 2017, the proportion of camel sera with
high VNT titers (> 320) in Israel was 27.3%, which is much lower than
the proportion of sera with high VNT titers in the surrounding coun-
tries, such as Saudi Arabia, Qatar, UAE, Oman, Egypt, and Jordan,
reaching to> 90% [2, 11–15.]. Moreover, the proportion of sera with
low VNT titers (< 320) in Israel was about 70.4%, whereas in in the
surrounding countries only about 10% of the sera had low VNT titers
meaning that the MERS-CoV seroprevalence in Israel is lower than that
in the surrounding countries. The diﬀerences in seropositivity by year
in Israel might be related to the camels included in the random sample.
In contrast, low seroprevalence and probably no virus circulation
were documented in the Canary Islands (14.3%) [14].
In the present study we showed for the ﬁrst time the presence of
MERS-CoV antibodies in naturally infected llamas by ELISA and VNT.
In our study 29.4 and 31.5% of Israeli alpacas and llamas, respectively,
were seropositive using the VNT assay. Using ELISA only 34.3 and
36.8% of alpacas and llamas, respectively were detected seropositive.
The two camels co-housed with the llamas and alpacas were negative
for antibodies and viral RNA using the two serological assays and PCR,
respectively. Previously MERS–CoV neutralizing antibodies were de-
tected in 15/15 alpacas in Qatar [16]. Similar to our ﬁndings, lower
neutralizing antibody titers were documented in alpacas and experi-
mentally infected llamas than in camels [5,16].
Using a MERS-CoV speciﬁc RT-PCR we detected no MERS-CoV
genomic RNA in the nasal swabs of camels, alpacas and llamas during
the period of 2015 to 2017 providing no evidence for active MERS-CoV
circulation.
5. Conclusions
Altogether, the relatively low prevalence of antibodies to MERS-
CoV, the low antibody titers, the absence of viral RNA in nasal swabs,
and the absence of disease in humans indicate, limited MERS-CoV
circulation in Israeli camelids in during the time of our survey.
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